Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EPI-326 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on EPI-326, a putative tissue-selective bispecific antibody targeting Egfr for degradation (Mar 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EPI-326 | EPI326|EPI 326 | Limited information is currently available on EPI-326, a putative tissue-selective bispecific antibody targeting Egfr for degradation (Mar 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07462377 | Phase I | EPI-326 | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | Recruiting | USA | 0 |